Bingham Private Wealth Boosts Johnson & Johnson Stake

Institutional investor adds to position in pharmaceutical giant

Apr. 19, 2026 at 7:07am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, interlocking gears and levers in a banking vault, conveying the complex financial infrastructure behind a major corporation's stock.Bingham Private Wealth's increased stake in Johnson & Johnson reflects institutional confidence in the healthcare giant's long-term growth potential.New Brunswick Today

Bingham Private Wealth LLC, a financial advisory firm, has purchased a new stake of 8,626 shares in Johnson & Johnson (NYSE: JNJ) during the fourth quarter, according to a recent 13F filing. The new position is valued at approximately $1.785 million and represents about 1.5% of Bingham's total holdings.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. Institutional investors closely monitor changes in ownership of blue-chip stocks like JNJ, as it can signal broader market trends and investor sentiment.

The details

Bingham Private Wealth LLC, an investment management firm, disclosed the new position in Johnson & Johnson in its latest 13F filing with the SEC. The firm purchased 8,626 shares of the company's stock during the fourth quarter of 2025. This new stake is valued at around $1.785 million, making it the 14th largest holding in Bingham's portfolio.

  • Bingham Private Wealth LLC purchased the new Johnson & Johnson shares during the 4th quarter of 2025.

The players

Bingham Private Wealth LLC

An investment management firm that purchased a new stake in Johnson & Johnson stock.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer products.

Got photos? Submit your photos here. ›

The takeaway

Bingham Private Wealth's increased investment in Johnson & Johnson reflects the firm's confidence in the healthcare giant's long-term growth potential. As a diversified conglomerate with leading positions across multiple sectors, JNJ remains a popular choice among institutional investors seeking stability and consistent returns.